Standard random effects meta-analysis comparison of efficacy and hepatotoxicity among various treatment regimens for treatment of latent tuberculosis (TB) infection
| Comparator | Intervention | Development of incident TB | Hepatotoxicity |
| Placebo | Isoniazid 6 months | 0.61 (0.48–0.77) | 0.99 (0.42–2.32) |
| Placebo | Isoniazid 12–72 months | 0.53 (0.41–0.69) | 0.59 (0.23–1.55) |
| Placebo | Rifampicin 3–4 months | 0.48 (0.26–0.87) | |
| Placebo | Rifampicin and isoniazid 3–4 months | 0.52 (0.33–0.84) | |
| Isoniazid 6 month | Rifampicin 3–4 months | 0.78 (0.41–1.46) | 0.03 (0.00–0.48) |
| Isoniazid 6 month | Rifampicin and isoniazid 3–4 months | 0.89 (0.65–1.23) | 0.89 (0.52–1.55) |
| Isoniazid 6 month | 3 month weekly rifapentine plus isoniazid# | 1.09 (0.60–1.99) | 1.00 (0.50–1.99) |
| Isoniazid 9 month | 3 month weekly rifapentine plus isoniazid | 0.44 (0.18–1.07) | 0.16 (0.10–0.27) |
Data are presented as odds ratios with 95% confidence intervals. #: exclusively among people living with HIV.